Videos

An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy.

Mazyar Shadman, MD, MPH, discusses the safety profile of BTK inhibitors in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Caitlin Costello, MD, looks to the future of treating patients with relapsed/refractory multiple myeloma, highlighting potential opportunities and challenges in the therapeutic landscape.

A hematologist-oncologist provides clinical advice to community-based clinicians on key strategies for optimizing the treatment of patients with relapsed/refractory multiple myeloma.

Caitlin Costello, MD, provides clinical insights on best practices for treating patients with relapsed/refractory multiple myeloma who receive early-line CAR T-cell therapy and later relapse.

Harry Erba, MD, PhD, discusses myeloMATCH, a precision medicine umbrella trial for patients with acute myeloid leukemia or myelodysplastic syndrome.

An expert on relapsed/refractory multiple myeloma discusses the role of stem cell transplantation in current treatment paradigms.

Following the recent approvals of ide-cel and cilta-cel CAR T-cell therapy for patients with relapsed/refractory multiple myeloma, a hematologist-oncologist discusses clinical research supporting their utilization.

Caitlin Costello, MD, presents the case of a 60-year-old woman with later relapsed/refractory multiple myeloma and discusses how the treatment landscape has evolved, highlighting remaining unmet needs.

Guillermo Garcia-Manero, MD, provides advice to community oncologists on the treatment of anemia for patients with lower-risk MDS.

An expert on lower-risk MDS discusses how the treatment of anemia is evolving as newer therapies enter the treatment landscape.

A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.

Dr Garcia-Manero offers insights on the adverse events profile associated with luspatercept in patients with lower-risk MDS.

Guillermo Garcia-Manero, MD, addresses clinical research investigating luspatercept dose titration practices in patients with lower-risk MDS.

A medical oncology specialist discusses how recent data and improvements in genomic profiling are changing the classification of lower-risk MDS.

Guillermo Garcia-Manero, MD, reviews recent results from the COMMANDS study investigating luspatercept versus epoetin alfa in patients with ESA-naïve, transfusion dependent LR-MDS.

An expert on the treatment of lower-risk MDS outlines practices for identifying patients who are suitable to receive erythroid maturating agents for treatment of anemia.

A medical oncologist discusses standard-of-care treatment practices for patients with lower-risk myelodysplastic syndromes.

Neel Bhatt, MBBS, MPH, discusses a study exploring long-term quality of life outcomes of patients who underwent stem cell transplantation for aplastic anemia.

Matthew Hadfield, DO, discusses his interest in immunotherapy and the toxicities associated with them.

The panelists compare the adverse event profiles of immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens, and address the economic implications of managing long-term side effects.

Following recent updates from the SEQUOIA Arm D and CAPTIVATE studies, Mazyar Shadman, MD, MPH, discusses the future implications of fixed-duration therapy for patients with CLL/SLL.

An expert on hematologic malignancies discusses the ongoing CAPTIVATE trial evaluating ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL.

Daniel Rubin, PharmD, discusses key takeaways from a study exploring the use. of a clinical decision tool for biomarker documentation.

Taiga Nishihori, MD, discusses a study in which investigators evaluated patients with relapsed/refractory multiple myeloma who were hospitalized and treated with commercial ciltacabtagene autoleucel at Moffitt Cancer Center between May 2022 and May 2023.

Vincent Law, research associate at Moffitt Cancer Center, discusses the key takeaways and implications of this research.

Corey Cutler, MD, MPH, and Hannah Choe, MD, provide future perspectives on the development of axatilimab for patients with chronic GVHD.

Alexandra Gomez Arteaga, MD, discusses the rationale behind a retrospective study comparing Orca-T with posttransplant cyclophosphamide-based hematopoietic cell transplantation.